Mass spectrometry-based comparative sequencing to detect ganciclovir resistance in the UL97 gene of human cytomegalovirus

Journal of Clinical Virology

Volumn 51, Issue 1, 2011, Pages 25-30

  Posthuma, Clara C ^a   van der Beek, Martha T ^a   van der Blij de Brouwer, Caroline S ^a   van der Heiden, Pim L J ^a   Marijt, Erik W A ^a   Spaan, Willy J M ^a   Claas, Eric C J ^a   Nederstigt, Christa ^a   Vossen, Ann C T M ^a   Snijder, Eric J ^a   Kroes, Aloys C M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antiviral drug resistance; Comparative sequencing; Human cytomegalovirus; Mass spectrometry; UL97

Indexed keywords

GANCICLOVIR; PHOSPHOTRANSFERASE;

AMPLICON; ANTIBIOTIC RESISTANCE; ARTICLE; AUTOMATION; CLINICAL ARTICLE; ENCEPHALITIS; ENZYME ACTIVATION; GENE SEQUENCE; HUMAN; HUMAN CYTOMEGALOVIRUS; MASS SPECTROMETRY; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; UL97 GENE; VIRUS GENE; VIRUS GENOME; VIRUS STRAIN;

ANTIVIRAL AGENTS; BASE SEQUENCE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GANCICLOVIR; GENOTYPE; HUMANS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MOLECULAR TYPING; MUTATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 79953733120     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.01.015     Document Type: Article

References (40)

1. Dolan A., Cunningham C., Hector R.D., Hassan-Walker A.F., Lee L., Addison C., et al. Genetic content of wild-type human cytomegalovirus. J Gen Virol 2004, 85:1301-1312.
2. Mocarski E.S., Shenk T., Pass R.F. Cytomegaloviruses. Fields virology 2007, 2701-2772. Lippincott Williams & Wilkins;, Philadelphia. 5 ed. D.M. Knipe, P.M. Howley (Eds.).
3. Boivin G., Goyette N., Gilbert C., Roberts N., Macey K., Paya C., et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004, 189:1615-1618.
4. Gilbert C., Roy J., Belanger R., Delage R., Beliveau C., Demers C., et al. Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients. Antimicrob Agents Chemother 2001, 45:3669-3671.
5. van der Beek M.T., Berger S.P., Vossen A.C.T.M., van der Blij-de Brouwer C.S., Press R.R., de Fijter J.W., et al. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. Transplantation 2010, 89:320-326.
6. Alain S., Hantz S., Scieux C., Karras A., Mazeron M.C., Szelag J.C., et al. Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection. J Med Virol 2004, 73:566-573.
7. Allice T., Busca A., Locatelli F., Falda M., Pittaluga F., Ghisetti V. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus. J Antimicrob Chemother 2009, 63:600-608.
8. Eid A.J., Arthurs S.K., Deziel P.J., Wilhelm M.P., Razonable R.R. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008, 22:162-170.
9. Limaye A.P., Corey L., Koelle D.M., Davis C.L., Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000, 356:645-649.
10. Nichols W.G., Corey L., Gooley T., Drew W.L., Miner R., Huang M., et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 2001, 97:867-874.
11. Springer K.L., Chou S., Li S., Giller R.H., Quinones R., Shira J.E., et al. How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. J Clin Microbiol 2005, 43:208-213.
12. van der Heiden P.L., Kalpoe J.S., Barge R.M., Willemze R., Kroes A.C., Schippers E.F. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant 2006, 37:693-698.
13. Crumpacker C.S., Ganciclovir N Engl J Med 1996, 335:721-729.
14. Biron K.K., Stanat S.C., Sorrell J.B., Fyfe J.A., Keller P.M., Lambe C.U., et al. Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci U S A 1985, 82:2473-2477.
15. Hamzeh F.M., Lietman P.S. Intranuclear accumulation of subgenomic noninfectious human cytomegalovirus DNA in infected cells in the presence of ganciclovir. Antimicrob Agents Chemother 1991, 35:1818-1823.
16. Erice A., Gil-Roda C., Perez J.L., Balfour H.H., Sannerud K.J., Hanson M.N., et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 1997, 175:1087-1092.
17. Lurain N.S., Bhorade S.M., Pursell K.J., Avery R.K., Yeldandi V.V., Isada C.M., et al. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis 2002, 186:760-768.
18. Chou S., Waldemer R.H., Senters A.E., Michels K.S., Kemble G.W., Miner R.C., et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis 2002, 185:162-169.
19. Jabs D.A., Martin B.K., Forman M.S., Dunn J.P., Davis J.L., Weinberg D.V., et al. Mutations conferring ganciclovir resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis 2001, 183:333-337.
20. Smith I.L., Cherrington J.M., Jiles R.E., Fuller M.D., Freeman W.R., Spector S.A. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 1997, 176:69-77.
21. Kalpoe J.S., Kroes A.C.M., de Jong M.D., Schinkel J., de Brouwer C.S., Beersma M.F.C., et al. Validation of clinical application of cytomegalovirus plasma DNA load measurement and definition of treatment criteria by analysis of correlation to antigen detection. J Clin Microbiol 2004, 42:1498-1504.
22. Honisch C., Chen Y., Mortimer C., Arnold C., Schmidt O., van den B.D., et al. Automated comparative sequence analysis by base-specific cleavage and mass spectrometry for nucleic acid-based microbial typing. Proc Natl Acad Sci U S A 2007, 104:10649-10654.
23. Lurain N.S., Weinberg A., Crumpacker C.S., Chou S. Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. Antimicrob Agents Chemother 2001, 45:2775-2780.
24. Borst E.M., Hahn G., Koszinowski U.H., Messerle M. Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J Virol 1999, 73:8320-8329.
25. Chou S. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Antimicrob Agents Chemother 2010, 54:2371-2378.
26. Chou S., Van Wechel L.C., Lichy H.M., Marousek G.I. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob Agents Chemother 2005, 49:2710-2715.
27. Lurain N.S., Spafford L.E., Thompson K.D. Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. J Virol 1994, 68:4427-4431.
28. Wolf D.G., Smith I.L., Lee D.J., Freeman W.R., Flores-Aguilar M., Spector S.A. Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J Clin Invest 1995, 95:257-263.
29. Chrisp P., Clissold S.P. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 1991, 41:104-129.
30. Foulongne V., Turriere C., Diafouka F., Abraham B., Lastere S., Segondy M. Ganciclovir resistance mutations in UL97 and UL54 genes of Human cytomegalovirus isolates resistant to ganciclovir. Acta Virol 2004, 48:51-55.
31. Bayliss J., Moser R., Bowden S., McLean C.A. Characterisation of single nucleotide polymorphisms in the genome of JC polyomavirus using MALDI TOF mass spectrometry. J Virol Methods 2010, 164:63-67.
32. Ganova-Raeva L., Ramachandran S., Honisch C., Forbi J.C., Zhai X., Khudyakov Y. Robust hepatitis B virus genotyping by mass spectrometry. J Clin Microbiol 2010, 48:4161-4168.
33. Yeo A.C., Chan K.P., Kumarasinghe G., Yap H.K. Rapid detection of codon 460 mutations in the UL97 gene of ganciclovir-resistant cytomegalovirus clinical isolates by real-time PCR using molecular beacons. Mol Cell Probes 2005, 19:389-393.
34. Gohring K., Mikeler E., Jahn G., Rohde F., Hamprecht K. Rapid semiquantitative real-time PCR for the detection of human cytomegalovirus UL97 mutations conferring ganciclovir resistance. Antivir Ther 2008, 13:461-466.
35. Liu J.B., Zhang Z. Development of SYBR Green I-based real-time PCR assay for detection of drug resistance mutations in cytomegalovirus. J Virol Methods 2008, 149:129-135.
36. Gorzer I., Guelly C., Trajanoski S., Puchhammer-Stockl E. Deep sequencing reveals highly complex dynamics of human cytomegalovirus genotypes in transplant patients over time. J Virol 2010, 84:7195-7203.
37. Julin J.E., van Burik J.H., Krivit W., Webb C., Holman C.J., Clark H.B., et al. Ganciclovir-resistant cytomegalovirus encephalitis in a bone marrow transplant recipient. Transpl Infect Dis 2002, 4:201-206.
38. Seo S.K., Regan A., Cihlar T., Lin D.C., Boulad F., George D., et al. Cytomegalovirus ventriculoencephalitis in a bone marrow transplant recipient receiving antiviral maintenance: clinical and molecular evidence of drug resistance. Clin Infect Dis 2001, 33:e105-e108.
39. Wolf D.G., Lurain N.S., Zuckerman T., Hoffman R., Satinger J., Honigman A., et al. Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipients. Blood 2003, 101:463-465.
40. Zeiser R., Grullich C., Bertz H., Pantazis G., Hufert F.T., Bley T.A., et al. Late cytomegalovirus polyradiculopathy following haploidentical CD34+-selected hematopoietic stem cell transplantation. Bone Marrow Transplant 2004, 33:243-245.